Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epidermolysis Bullosa Dystrophica, Recessive Clear all
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
FCX-007
Genetic
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced May 22, 2026, 1:11 AM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced May 22, 2026, 1:11 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
Helicoll, Standard of Care Dressings
Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Open Label Topical Beremagene Geperpavec (B-VEC)
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced May 22, 2026, 1:11 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions
QR-313, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced May 22, 2026, 1:11 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
12 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced May 22, 2026, 1:11 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Topical Beremagene Geperpavec, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced May 22, 2026, 1:11 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 1:11 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
Immunoglobulin G
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
6 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:11 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 1:11 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
Efgartigimod
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Redwood City, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced May 22, 2026, 1:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 1:11 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Interventions
EB-101 Surgical application of RDEB wounds
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
12 Months and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced May 22, 2026, 1:11 AM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
7 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced May 22, 2026, 1:11 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
online survey
Other
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 22, 2026, 1:11 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 1:11 AM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
PTW-002 10 mg/g gel, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced May 22, 2026, 1:11 AM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
RDEB
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced May 22, 2026, 1:11 AM EDT